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The 50-Year History, Controversy, and
Clinical Implications of Left Ventricular Outflow
Tract Obstruction in Hypertrophic Cardiomyopathy
From Idiopathic Hypertrophic Subaortic Stenosis
to Hypertrophic Cardiomyopathy
Barry J. Maron, MD,* Martin S. Maron, MD,† E. Douglas Wigle, OC, MD,§
Eugene Braunwald, MD‡
Minneapolis, Minnesota; Boston, Massachusetts; and Toronto, Ontario, Canada
Dynamic obstruction to left ventricular (LV) outflow was recognized from the earliest (50 years ago) clinical de-
scriptions of hypertrophic cardiomyopathy (HCM) and has proved to be a complex phenomenon unique in many
respects, as well as arguably the most visible and well-known pathophysiologic component of this heteroge-
neous disease. Over the past 5 decades, the clinical significance attributable to dynamic LV outflow tract gradi-
ents in HCM has triggered a periodic and instructive debate. Nevertheless, only recently has evidence emerged
from observational analyses in large patient cohorts that unequivocally supports subaortic pressure gradients
(and obstruction) both as true impedance to LV outflow and independent determinants of disabling exertional
symptoms and cardiovascular mortality. Furthermore, abolition of subaortic gradients by surgical myectomy (or
percutaneous alcohol septal ablation) results in profound and consistent symptomatic benefit and restoration of
quality of life, with myectomy providing a long-term survival similar to that observed in the general population.
These findings resolve the long-festering controversy over the existence of obstruction in HCM and whether out-
flow gradients are clinically important elements of this complex disease. These data also underscore the impor-
tant principle, particularly relevant to clinical practice, that heart failure due to LV outflow obstruction in HCM is
mechanically reversible and amenable to invasive septal reduction therapy. Finally, the recent observation that
the vast majority of patients with HCM have the propensity to develop outflow obstruction (either at rest or with
exercise) underscores a return to the characterization of HCM in 1960 as a predominantly obstructive
disease. (J Am Coll Cardiol 2009;54:191–200) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.069(
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Lt has now been more than 50 years since the first modern
escriptions of hypertrophic cardiomyopathy (HCM) by
rock (1), in 1957, based on hemodynamics at cardiac
atheterization or operation, and by Teare (2), in 1958,
rom the autopsy laboratory. Over that considerable period
f time, literally thousands of reports have been published
escribing various elements of HCM (3–16). Consequently,
e now recognize HCM to be the most common familial
eart disease characterized by substantial heterogeneity with
espect to presentation, phenotypic expression, clinical
ourse, and genetic substrate, as well as the management
trategies applicable to this broad clinical spectrum.
rom the *Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute
oundation, Minneapolis, Minnesota; †Hypertrophic Cardiomyopathy Center, Tufts
edical Center, and ‡TIMI Study Group, Brigham and Women’s Hospital, Harvard
edical School, Boston, Massachusetts; and the §Division of Cardiology, Toronto
eneral Hospital, Toronto, Ontario, Canada.c
Manuscript received April 29, 2008; revised manuscript received November 12,
008, accepted November 12, 2008.Following initial reports from Brock (1) and others
3,17–19) describing intraventricular systolic pressure gra-
ients regarded as examples of “functional stenosis of the
eft ventricle,” dynamic obstruction to left ventricular (LV)
utflow rapidly achieved distinction as the most visible
eature of HCM, dominating the initial comprehensive
escription of the disease (4) and other early reports.
owever, outflow pressure gradients have also been the
ource of periodic and often intense controversy regarding
heir clinical and pathophysiologic significance (20–23).
ndeed, this uncertainty surrounding obstruction is typical
f the considerable confusion that in many other ways has
lso influenced the understanding of this complex disease
ithin the cardiovascular community (5). Therefore,
aving recently celebrated the 50th (golden) anniversary
f HCM, it seems particularly appropriate to revisit and
ocus attention on the evolution in our understanding of
V outflow obstruction, which has profoundly affected
linical practice.
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History of Obstruction in HCM July 14, 2009:191–200Historical Context
Virtually from initial recognition
in the late 1950s, dynamic ob-
struction to LV outflow has been
regarded as an integral compo-
nent of HCM (Fig. 1). In fact, in
the early pre-echocardiographic
era (1960 to 1969), an outflow
radient was a virtual prerequisite for the diagnosis of
CM, either by physical examination (e.g., auscultation of
he characteristic systolic murmur) or by invasive measure-
ent of a peak systolic pressure gradient between LV cavity
nd proximal outflow tract (4) (Fig. 2). Indeed, the nonob-
tructive form of HCM, although recognized in the early
960s (24,25), received little attention until the emergence
f M-mode echocardiography in the early 1970s (26–31).
Adding to the mystique surrounding obstruction in
CM has been its dynamic nature (first described in 1962)
32), in which pressure gradients can vary considerably with
variety of pharmacologic and physiologic provocations
hat reduce peripheral arterial pressure or ventricular vol-
me, or enhance myocardial contractility, and may change
ven after heavy meals or alcohol intake or spontaneously on
day-to-day or hour-to-hour basis (4,32–34). Almost from
he inception, it was recognized that dynamic outflow
radients could be provoked by physiologic exercise (4,35)
r a variety of nonphysiologic maneuvers including sympa-
homimetic agents, such as infused isoproterenol or dobut-
mine, or by introducing premature ventricular beats, amyl
itrite inhalation or nitroglycerin, as well as the Valsalva
aneuver (4,36).
With the possible exception of disopyramide (37), drug
herapy does not reliably mitigate intraventricular pressure
radients (5) under basal (resting) conditions although
eta-blockade is known to blunt gradients provoked with
xercise (4). Spontaneous and permanent loss of outflow
bstruction appears to be largely confined to those circum-
Abbreviations
and Acronyms
HCM  hypertrophic
cardiomyopathy
LV  left ventricular
SAM  systolic anterior
motion
Figure 1 Timeline
Timeline summarizes major events that comprise the history of left ventricular out
of Cardiology; AHA  American Heart Association; DDD  dual-chamber; echo  etances in which substantial LV remodeling occurs, such as
ith progression to the end-stage phase when systolic
ysfunction appears (38,39). Conversion from the nonob-
tructive to obstructive state may be evident during adoles-
ence, with the development of the HCM phenotype, at the
ime of accelerated growth and maturation (40).
Initially, several names were promoted to describe this
isease entity, each of which is dependent on the presence of
bstruction: idiopathic hypertrophic subaortic stenosis in
he U.S., muscular subaortic stenosis in Canada, and hyper-
rophic obstructive cardiomyopathy in the United Kingdom
41). These terms persist occasionally, but rarely appear in
he current literature. Indeed, hypertrophic cardiomyopathy
redominates as the formal name for this disease (41),
ecause this terminology is inclusive allowing for both the
bstructive and nonobstructive forms of the disease.
ontroversy and Dilemma
lthough dynamic LV outflow gradients have been widely
ecognized as clinical markers of HCM since the early
960s, considerable controversy rapidly developed (20,23,
2–46) concerning the clinical implications of intraventric-
lar pressure differences that were identified with increasing
requency in the catheterization laboratory and believed to
esult from excessive muscular constriction of the proximal
utflow tract (18). Indeed, in an early description of surgical
yotomy and myectomy in the treatment of HCM, Mor-
ow et al. (47) stated that “when the finger is introduced into
he left ventricle, the muscle mass is usually felt to be
emispherical. . .forceful contraction of the outflow tract
pon the examining finger is evident during systole.” There-
ore, even though recognition of outflow gradients was
ltimately the impetus for the septal myectomy operation,
aradoxically, the surgical strategy of muscular resection was
riginally devised to interrupt the outflow tract “contraction
ing” before the recognition 7 to 10 years later that systolic
ct obstruction in hypertrophic cardiomyopathy. ACC  American College
rdiography; LVH  left ventricular hypertrophy; SAM  systolic anterior motion.flow tra
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July 14, 2009:191–200 History of Obstruction in HCMnterior motion of the mitral valve was actually the mech-
nism of obstruction (29–31,48).
Even the very existence of LV obstruction in this new
isease was seriously questioned (20,21) and became a major
nd contentious controversy in cardiovascular medicine at the
966 American Heart Association meeting in New York that
evoted a full 90-min session to this topic as the only scheduled
rogram event at that time, attracting virtually all meeting
ttendees (Fig. 1). Michael Criley (20) of Johns Hopkins
Figure 2 Identification of LV Outflow Tract Gradients in HCM
(A) Cardiac catheterization pull-back tracing from left ventricular (LV) cavity to outfl
sion, from Braunwald et al. (4). (B) Data from early National Institutes of Health e
gradients post-operatively. (C) Provocation of outflow gradients following physiolog
without marked obstruction at rest. Each patient is depicted by a line connecting t
al. (35). (D) Development of marked obstruction provoked by exercise, and at rest
tole) (I) with normal Doppler velocity in the outflow tract (III). After exercise, demo
(gradient: 100 mm Hg) (IV). Reprinted, with permission, from Maron et al. (35). IH
operation; PREOP  before operation; PTS  patients; RA  right atrium; RV  rigospital, the first skeptic to question the legitimacy of obstruc- wion, argued that the outflow gradient in HCM did not
epresent true mechanical impedance, but rather was the
onsequence of premature, excessively rapid ejection from a
igorously contracting LV (“pressure gradients without ob-
truction”). This position was summarized as follows: exces-
ively rapid ejection with systolic obliteration of portions of the
V cavity itself provides a sufficient explanation for pressure
radients and is compatible with all available hemodynamic
nd angiographic observations, while belief in obstruction
ct to aorta, recording intraventricular pressure gradient. Reprinted, with permis-
nce with surgical myectomy showing virtual obliteration of resting LV outflow tract
cise in a consecutive group of 201 hypertrophic cardiomyopathy (HCM) patients
dient measurements.  mean. Reprinted, with permission, from Maron et
l 5-chamber view showing mitral valve at end-diastole (SAM was absent in sys-
ing typical SAM-septal contact (II; arrow) with corresponding velocity of 5 m/s
idiopathic hypertrophic subaortic stenosis; LA  left atrium; POSTOP  after
tricle; VS  ventricular septum; other abbreviations as in Figure 1.ow tra
xperie
ic exer
wo gra
. Apica
nstrat
SS 
ht venould ultimately impede a full understanding of HCM (21).
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History of Obstruction in HCM July 14, 2009:191–200Alternatively, others asserted that the pressure gradients
easured in the laboratory could also represent artifacts
roduced when the catheter becomes physically enfolded
nd entrapped within recesses of hypertrophied LV trabe-
ulations during vigorous isometric contraction (in the
resence of distal cavity obliteration), recording intramural
ather than intracavity systolic pressure.
Challenges to the presence of obstruction in HCM cast
oubt on the prudence associated with early surgical at-
empts at relieving obstruction (49–51). However, Ross and
raunwald (then of National Institutes of Health) (42) and
igle (43,45), strongly opposed this view, defending the
egitimacy of the outflow gradient with several avenues of
vidence: the characteristically prolonged LV ejection time
n the presence of gradients (45), and demonstration that a
ransseptal catheter passed through the mitral orifice into
he nonobliterated LV inflow area recorded systolic pres-
ures identical to those in the distal chamber. The latter
bservation was critical because it demonstrated that ele-
ated systolic pressures were not limited to empty regions of
he LV and, in the process, refuted the Criley hypothesis
hat gradients were only a consequence of cavity obliteration
20,21).
Although a general consensus began to emerge that true
bstruction occurred in patients with HCM and operative
ntervention (with ventricular septal myectomy or myotomy)
as a valid strategy by which severe heart failure-related
ymptoms could be relieved by abolition of the outflow
radient (4,46,47,49 –51), investigators at Hammersmith
ospital (London) continued to be highly vocal oppo-
ents of obstruction and critics of myectomy surgery until
nly very recently, persisting in the view that outflow
radients were simply incidental to the clinical disease
rocess (9,31,33).
ontributions of Echocardiography
oninvasive echocardiographic imaging was introduced to
CM from 1969 to 1973 demonstrating the characteristic
symmetric pattern of LV hypertrophy (26–28), systolic
nterior motion (SAM) of the mitral valve as the mecha-
ism by which obstruction occurs (29–31,52,53) (although
rst identified with angiography [42,48,54]), as well as
nderscoring that the nonobstructive form is a substantial
art of the HCM disease spectrum. Systolic anterior motion
nd mitral-septal contact, usually produced by the leading
dge of anterior mitral leaflet (29–31,52,53,55) (but in some
atients by the posterior leaflet) (56), is responsible for
bstruction to LV outflow in 95% of cases (55). Midcavity
bstruction may also occur in the absence of SAM (57,58)
ue to muscular apposition or anomalous insertion of the
nterolateral papillary muscle directly into anterior mitral
eaflet (59). In virtually all patients, SAM redirects a fraction
f LV stroke volume into the left atrium, producing
econdary (and posteriorly directed) mitral regurgitation,
he magnitude of which is usually related to the severity of tbstruction (46,54,60). Determinants of SAM and outflow
bstruction include the vigorous LV ejection, as well as the
nusual chamber geometry and morphology (40,61,62): 1)
educed outflow tract cross-sectional area (to which the
ypertrophied septum contributes); 2) exaggerated anterior
isplacement of the mitral valve apparatus and papillary
uscles; and 3) primary enlargement and elongation of
itral leaflets.
Such insights from echocardiographic imaging raised
linical awareness and increased the number of patients
iagnosed with obstructive HCM, resulting in greater
umbers of candidates for surgical septal myectomy. Pros-
hetic mitral valve replacement has been promoted as a
rimary surgical strategy to relieve obstruction and symp-
oms (63). However, enthusiasm for this strategy was
hort-lived and ultimately abandoned due to the potential
ong-term post-operative complications of prosthetic valves
64). Mitral valve replacement has a role only in those
xceedingly rare patients in whom the anterior basal septum
s not sufficiently thickened to permit an effective and safe
uscular resection (65).
kepticism and Controversy Returns
ased on the 1980 study of Murgo et al. (22), controversy
egarding the significance of LV outflow gradients re-
merged after almost 20 years, predicated largely on the
riley premise that early LV ejection and cavity emptying
nd powerful contraction were responsible for outflow
radients, in the process triggering old doubts about the
egitimacy of surgical intervention in this disease. This
emodynamic investigation, performed in a small number
f HCM patients, used novel catheter-mounted electro-
agnetic flow meters, as well as high-fidelity catheters to
ecord LV and aortic pressures. Reporting mid-systolic
eceleration of forward flow in both patients with and
ithout subaortic gradients (but not in normal controls),
urgo et al. (22) concluded that LV outflow gradients in
CM (and presumably mitral valve SAM) were incidental
o the disease process. However, these data were soon
ontradicted by studies assessing ascending aorta Doppler
nstantaneous flow velocity (66).
Reignited by these findings, the old obstruction debate
as publicly resurrected in a panel discussion at the 1984
merican College of Cardiology meeting in Dallas dedi-
ated to the question: Is there obstruction in HCM? The
ebate pitted Murgo and Oakley against Wigle and Maron
Fig. 1). Although much of the session was dominated by a
etailed discussion of flow dynamics and ventricular me-
hanics, the Murgo hypothesis ultimately failed to answer
he fundamental clinical question implicit in the debate: if
ubaortic gradients are pathophysiologically irrelevant fea-
ures of HCM, how can that assertion be consistent with
he extensive and favorable operative experience from sur-
ical centers throughout the world reporting marked symp-
omatic benefit following relief of the intraventricular pres-
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July 14, 2009:191–200 History of Obstruction in HCMure gradient (by myectomy)? Furthermore, in view of
ompelling surgical data, would it not be unethical to
eny an operation known to be efficacious to severely
ymptomatic drug-refractory patients, based solely on the
rgument of whether it is proper to equate “gradient”
ith “obstruction”? It was concluded that increased
ntraventricular systolic pressure is the most important
athophysiologic component of the complex ejection
ynamics that occur in HCM.
Another popular (but flawed) anti-obstruction position,
hich also suppressed the myectomy option and may
ave deprived some patients of potentially beneficial
reatment, noted that patients with the obstructive or
onobstructive forms could both experience progressive
eart failure symptoms and concluded from this obser-
ation that the gradient was not a clinically important
eature of the disease (9,67). However, this critique
gnored the important pathophysiologic principle that
utflow obstruction is just 1 of the possible determinants
f heart failure symptoms in HCM, and other mecha-
isms such as impaired diastolic filling and myocardial
schemia can be responsible for exertional limitation in
he absence of obstruction (5,68,69).
he Dual-Chamber Pacing Controversy
ebate over outflow obstruction in HCM continued in
he early 1990s in the context of dual-chamber (DDD)
acing to relieve subaortic gradients and severe heart
ailure-related symptoms refractory to maximal medical
anagement (70 –76). Observational, uncontrolled stud-
es heavily promoted pacing as a strategy to alter the
atural course of the disease (72). Several reports de-
cribed dramatic reduction in both gradient (often to 0)
nd functional disability, and it was suggested that the
echanism by which pacing reduced subaortic obstruc-
ion was likely asynchronous ventricular septal activation.
However, several randomized double-blind cross-over
tudies showed that the perceived symptomatic benefit from
acing largely represented a placebo effect (74–76), and
eduction in gradient was both inconsistent and generally
nly modest. In 1 study (75), elderly patients appeared to
erive true short-term benefit from dual-chamber pacing,
hich remains a therapeutic option for some patients in this
ubgroup on a case-by-case basis, or selectively in severely
ymptomatic patients who are not candidates for surgical
eptal myectomy. The pacing era and the controversy it
enerated, nevertheless, once again focused substantial at-
ention on the clinical significance of obstruction in HCM,
ts pathophysiologic role in the genesis of symptoms, and
he importance of reducing outflow gradients in severely
ymptomatic patients.
linical Evidence Resolves the Controversy
esidual ambivalence concerning the clinical and hemody-
amic significance of obstruction and the importance of eurgical myectomy (or more recently, selective alcohol septal
blation) as treatment strategies (77,78) has been resolved
y a series of clinical investigations in the last several years.
chocardiography Doppler studies. Several noninvasive
maging studies (79–88) have presented overwhelming
vidence for true obstruction and significant LV pressure
verload in HCM (Fig. 3). 1) The LV is not devoid of
lood in mid-to-late systole after an early rapid systolic
jection phase, but conversely a large (but highly variable)
roportion of stroke volume (about 50%) remains to be
jected when the gradient is present and is mechanically
mpeded in its egress by SAM-septal contact; the earlier and
ore prolonged the septal contact, the greater is the
bstructed flow. 2) Systolic anterior motion is a primary
vent, timed to the onset of the pressure gradient, and not
econdary to cavity obliteration. 3) Forward flow persists
hroughout systole (to aortic valve closure), with ejection
ime prolonged and related to the magnitude of the gradi-
nt. 4) Ejection dynamics in nonobstructive HCM and
ormal subjects are virtually identical. 5) Biphasic aortic
ow patterns and mid-systolic drop in LV ejection velocity
re consistent with the “spike and dome” arterial pulse and
id-systolic aortic valve closure. 6) Increased LV outflow
ract cross-sectional area created by muscular (myectomy)
esection abolishes SAM, the pressure gradient (and
itral regurgitation). 7) A quantitative relationship is
vident between time of onset and duration of SAM-
eptal contact and the magnitude of the gradient. 8)
oppler echocardiography reliably estimates gradient
sing the Bernoulli equation, virtually eliminating need
or routine cardiac catheterization. Finally, SAM (and
bstruction) is caused by hydrodynamic forces on the
itral valve, with drag (i.e., pushing force of flow)
81,83) predominant over the Venturi effect (i.e., mitral
eaflets sucked toward the septum by a high velocity
utflow jet) (85,89).
ulticenter cohort studies. Most importantly, over the
ast several years, clinical studies performed in large HCM
atient populations (not previously available in the HCM
iterature) (90–95) have identified a consistent relationship
etween LV outflow tract gradients at rest and heart failure
ymptoms and cardiovascular events. For example, a 2003
ong-term follow-up of a large HCM cohort of 1,100
atients established highly significant linkage between peak
nstantaneous LV outflow obstruction (gradient 30 mm
g at rest) and unfavorable outcome (90) (Fig. 4). Overall
robability of death due to HCM was significantly greater
mong patients with outflow obstruction than in those
ithout obstruction (relative risk [RR]: 2.0), as was pro-
ression to severe New York Heart Association functional
lass III or IV symptoms or death from heart failure or
troke (RR: 4.4). These disease complications were most
ommon in patients 40 years old, suggesting that longer
uration of obstruction promotes more adverse disease
onsequences. However, increasingly higher resting gradi-
nts 30 mm Hg did not increase the likelihood of
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History of Obstruction in HCM July 14, 2009:191–200nfavorable outcome. In addition, a weaker association
as been identified between outflow gradients and spe-
ifically sudden and unexpected death (usually in patients
ith no or only mild limiting symptoms) (90,91). Sub-
equent analysis in a smaller Italian HCM cohort offered
onfirmation that outflow obstruction was a strong and
ndependent predictor of cardiovascular mortality, partic-
larly in those patients without significant symptoms at
Figure 3 Evidence That Subaortic Gradients Represent Impeda
(A) Composite flow-velocity waveforms in the ascending aorta from patients wi
from the curves for normal subjects and nonobstructive HCM with characteristi
[SAM]), and the late lower flow phase. Reprinted, with permission, from Maron
patient with obstruction (gradient: 85 mm Hg). Arrow indicates onset of SAM-s
mission, from Pollick et al. (85). (C) Direct relation between corrected left ven
permission, from Sasson et al. (84). (D) Direct relation between magnitude of
permission, from Pollock et al. (85). AO  (central) aortic pressure; IVS  inte
rior wall; other abbreviations as in Figure 2.tudy entry (92) (Fig. 4). oAnother multicenter study used stress echocardiography
o assess physiologically provocable outflow gradients and
dentified 70% of HCM patients with the propensity to
evelop outflow obstruction either at rest or with exercise
35) (Fig. 2). These data represent a paradigm shift in our
nderstanding of the frequency with which outflow gradi-
nts occur in HCM, supporting the contemporary view that
his disease should be regarded as one in which outflow
o LV Outflow
tructive or nonobstructive HCM and normal subjects. Obstructive curve differs
rapid emptying, mid-systolic deceleration (due to systolic anterior motion
(88). (B) Simultaneous hemodynamic and echocardiographic recordings in a
contact, simultaneous with onset of pressure gradient. Reprinted, with per-
r ejection time (LVETc) and peak systolic pressure gradient. Reprinted, with
ure gradient (PG) and duration of SAM-septal contact (SSC). Reprinted, with
icular septum; LV  left ventricular pressure; MV  mitral valve; PW  poste-nce t
th obs
c early
et al.
eptal
tricula
press
rventrbstruction predominates (35).
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July 14, 2009:191–200 History of Obstruction in HCMBased on substantial post-operative surgical data as-
embled for septal myectomy (and with shorter follow-up
or alcohol septal ablation [77,78]), the relief of outflow
bstruction and normalization of LV systolic pressure
Fig. 2) is accompanied by long-lasting reduction in
isabling symptoms of heart failure (77). This is associ-
ted with objective improvement in myocardial metabo-
ism, oxygen consumption, and exercise capacity (96,97).
urthermore, and of particular importance, myectomy
onveys a long-term survival benefit, as demonstrated
ost recently by retrospective, nonrandomized, post-
perative studies from Mayo Clinic (93,98) and Toronto
eneral Hospital (94) in 1,600 patients. In the larger
ayo Clinic series, 10-year overall survival after myec-
omy was 83% (freedom from all-cause mortality), which
Figure 4 Data From HCM Cohort Studies Supporting the Clinica
(A) Kaplan-Meier estimates showing greater probability of progression to sever
death from heart failure or stroke among patients with outflow obstruction (gra
international multicenter study comprising 1,101 patients (90). Reprinted, with
of patients with LV obstruction at rest who died of cardiovascular causes exce
al. (91). (C) From the multicenter study depicted in A, showing effect of age a
or death from heart failure or stroke. Reprinted, with permission, from Maron e
undergoing surgical septal myectomy results in survival (depicted with respect
tion, and exceeding HCM patients with outflow obstruction who were not opera
Figure 2.as equivalent to that expected in the general U.S. eopulation (Fig. 4) and also superior to that of patients
ith obstructive HCM who were not operated on (10-
ear survival only 61%) (93); freedom from HCM mor-
ality following myectomy was 95%. Therefore, surgical
bolition of obstruction was strongly and independently
ssociated with survival, and myectomy reduced the
ortality risk in severely symptomatic patients with
bstruction; also, progression to the end-stage with
ystolic dysfunction and remodeling is no more common
ollowing myectomy than in the general HCM popula-
ion (40). Taken together, these data substantiate that
yectomy with relief of mechanical obstruction favorably
lters the basic disease course, definitively refuting any
onsideration that obstructive HCM represents a pro-
ressive heart muscle disorder with continued LV remod-
nificance of LV Outflow Gradient
rt failure (New York Heart Association [NYHA] functional class III or IV) or
30 mm Hg at rest) compared with patients without obstruction. From an
ission, from Maron et al. (90). (B) Italian study showing that the proportion
at of patients without obstruction. Reprinted, with permission, from Autore et
outflow tract obstruction on probability of progression to severe heart failure
90). (D) Abolition of LV outflow gradient in severely symptomatic patients
cause mortality) similar to that expected in a matched general U.S. popula-
. Reprinted, with permission, from Ommen et al. (93). Abbreviations as inl Sig
e hea
dient 
perm
eds th
nd LV
t al. (
to all-
ted onling, despite the best available treatment interventions (5).
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History of Obstruction in HCM July 14, 2009:191–200urrent Management Strategies
or LV Outflow Obstruction
he numerous clinical studies assembled over the past 50 or
ore years have ultimately led to the contemporary diag-
ostic and management strategies for LV outflow tract
bstruction, which are now part of standard clinical practice
5). In particular, the data that have recently emerged in
arge patient cohorts confirmed that LV outflow obstruction
at rest) is an important determinant of cardiovascular
orbidity and mortality in HCM patients (90–98), thereby
nderscoring the importance of properly identifying and
ggressively treating (and abolishing) subaortic gradients in
everely symptomatic and drug refractory patients by surgi-
al septal myectomy or, alternatively and selectively, by
lcohol septal ablation.
In addition, those LV outflow gradients commonly in-
uced with physiologic exercise by stress echocardiography
re often of clinical importance (35). Though many such
atients are asymptomatic (35), others may develop progres-
ive heart failure symptoms with exertion due to physiolog-
cally provoked outflow obstruction and may benefit from
eptal reduction intervention in a fashion similar to that of
atients with more typical obstruction under resting condi-
ions (5,35,77,99). Taken together, these principles sur-
ounding outflow obstruction in HCM are also supported
y current American College of Cardiology/European So-
iety of Cardiology expert consensus recommendations (5)
tating that invasive septal reduction therapy should be
eserved for those patients with advanced heart failure
ymptoms refractory to maximum pharmacologic therapy
principally with beta-blockers, verapamil, or disopyr-
mide): New York Heart Association functional class III or
V associated with a peak instantaneous outflow gradient50
m Hg at rest or with physiologic (exercise) provocation.
The more modest (but statistically significant) relationship
etween LV outflow gradient (at rest) and the risk for sudden
ardiac death (90,92) is not sufficiently strong to establish LV
utflow obstruction as an independent risk factor or justify
ecisions for primary prevention implantable-defibrillators
ased either solely or predominantly on the presence of a
ubaortic gradient (100). Marked outflow gradients can,
owever, be a supplemental factor and arbitrator in such
ecisions for patients with other risk factors and ambiguous
isk stratification on a case-by-case basis.
Over the last 10 years, with the emergence of percutane-
us alcohol septal ablation, a controversy has ensued con-
erning the most effective strategy for reducing or abolishing
V outflow tract gradients and severe heart failure symp-
oms unresponsive to maximum medical management
77,78). Surgical myectomy, which has been used for almost
0 years, and alcohol ablation both reduce outflow obstruc-
ion, and interventions that substantially mitigate gradient
an also be expected to reduce symptoms. The risk for
rocedural death and complications is comparable for both
echniques, if not higher for ablation. Most importantly,blation (in contrast to myectomy) creates a sizeable trans-
ural myocardial infarction comprising about 10% of the
V, which could serve as a substrate for potentially life-
hreatening ventricular tachyarrhythmias and sudden death.
onsequently, an expert consensus panel has retained sur-
ical myectomy as the primary treatment for patients with
bstructive HCM and unrelenting symptoms, with alcohol
blation reserved as an alternative option for those patients
ho are judged not to be appropriate surgical candidates (5).
onclusions
nderstanding the significance and frequency of LV out-
ow obstruction in patients with HCM has indeed been a
winding road,” but one that has eventually provided clini-
ally relevant answers directly related to patient manage-
ent. Indeed, we have come full circle to the positions held
n the early 1960s that HCM can be characterized as a
redominantly obstructive disease, and that outflow gradi-
nts are of pathophysiologic significance and often represent
therapeutically reversible form of mechanical obstruction
o LV outflow and heart failure.
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